查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1138297

2022-2029 年全球甲型肝炎疫苗市场

Global Hepatitis A Vaccine Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 190 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

政府加大预防力度

甲型肝炎疫苗用于阻止不断上升的甲型肝炎病例。根据美国疾病控制与预防中心的数据，2018 年美国共报告了 12,474 例甲型肝炎病例，加上未确诊病例，该机构估计年度报告的实际数量为 24,900 例。这就是为什么政府正在加紧努力提高认识、诊断、治疗和接种疫苗。截至 2022 年 4 月 21 日，世卫组织欧洲区域的 11 个国家和世卫组织美洲区域的 1 个国家报告了至少 169 例原因不明的急性肝炎病例。据世界卫生组织称，在卫生和个人卫生习惯不足的发达国家，大约 90.0% 的儿童在 10 岁时感染了甲型肝炎病毒。政府的疫苗接种计划正在推动发展中国家甲型肝炎疫苗的全球市场。

另一方面，缺乏个人对甲型肝炎的认识预计将成为预测期内抑制全球市场增长的主要因素。此外，居民对诊断的抵制也阻碍了市场的增长。

本报告提供了大约 48 个市场数据表、43 个图表和 190 页有关全球甲型肝炎疫苗市场的信息。

内容

第一章调查方法及范围

  • 调查方法
  • 市场范围

第 2 章主要趋势和发展

第 3 章执行摘要

  • 按产品类型划分的市场细分
  • 按应用划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
    • 约束因素
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • PEST 分析
  • 定价分析
  • 报销分析
  • 监管分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章按产品类型

  • 灭活□□疫苗
  • 减毒活疫苗

第 8 章按应用程序

  • 政府机构
  • 私营公司
  • 其他

第 9 章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 10 章竞争格局

  • 竞争场景
  • 竞争对手战略分析
  • 市场情况/份额分析
  • 併购分析

第 11 章公司简介

  • GlaxoSmithKline
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Merck & Co., Inc.
  • Sanofi
  • Sinovac
  • Zhejiang Pukang
  • Changchun Institute of Biological
  • KM Biologics
  • IMBCA
  • ChangSheng
  • Convac

第12章 DataM

简介目录
Product Code: DMPH3111

Market Overview

Hepatitis A Vaccine Market size was valued at USD 876.9 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 3.5% over the forecast period 2022 to 2029.

Hepatitis A vaccine is a vaccine that prevents hepatitis A. The disease is a liver disorder caused by the hepatitis A virus leading from mild to severe illness. The Hepatitis A Virus (HAV) is transferred through either ingestion of contaminated food and water or direct contact with an infectious person. The disease has a propensity for cyclic reappearances, which occurs in epidemics globally. The antibodies introduced in response to the disease lasts through life and protect against recurrence of infection, the best way for which is through vaccination. It is given in two doses injected six months apart. The major factors propelling the growth of the Hepatitis A vaccine market are the increasing prevalence of hepatitis A globally, which leads to increasing concerns for vaccination. The rise in the number of Hepatitis A cases propels the national governments and healthcare organizations to introduce steps to increase awareness about the disease and manage vaccination drives in the risk-prone areas. Further continuous efforts by the market players to promote Hepatitis A vaccines drive the market growth.

Market Dynamics: Increasing government initiatives for prevention

Hepatitis A Vaccine is used to submerge the rising cases of Hepatitis A. As per the Center for Disease Control, in 2018, the U.S. reported a total of 12,474 hepatitis A cases, and the organization estimated the actual number of cases reported in the year to be 24,900 owing to the undiagnosed cases. This has propelled governments to increase their efforts for awareness, diagnosis, treatment, and vaccination. As of 21 April 2022, at least 169 cases of acute hepatitis of unknown origin have been reported from 11 countries in the WHO European Region and one country in the WHO Region of the Americas. According to the WHO, approximately 90.0% of children are infected with the hepatitis A virus before 10 years in developed countries with inadequate sanitary conditions and sanitation habits. Government vaccination programs are propelling the worldwide market for hepatitis A vaccines in developing countries.

On the other hand, lack of awareness concerning the Hepatitis A disease among individuals is a key factor expected to curtail the global market's growth over the forecast period. Moreover, resistance among the population for diagnosis also obstructs market growth.

Market Segmentation: Inactivated vaccine segment is projected to be the dominant segment in the market during the forecast period

Inactivated vaccines dominated the global market in 2019, also it is expected to present considerable growth shortly. Inactivated Vaccines are safe and highly functional. A two-dose schedule is traditionally recommended, particularly for travelers at significant risk of contracting hepatitis A and immunocompromised individuals. However, with a single dosage, equivalent efficacy has been achieved in stable people. This is expected to propel segmental growth soon.

Based on application, government institutions held the dominant position in the global market during the forecast period. Patients depend on public healthcare facilities for diagnosis and proper vaccination of Hepatitis A, supporting the segment growth during the forecast period. Moreover, the surging government programs offering vaccination drives are expected to project a considerable CAGR during the forecast period.

Geographical Penetration: Asia-Pacific is expected to dominate the global Hepatitis A Vaccine market

Asia-Pacific held a dominant position in the global Hepatitis A Vaccine market in 2021. In Asia-Pacific, China is expected to represent considerable growth during the forecast period. As in China, the live attenuated Hepatitis A Vaccine is becoming a favorable element to tackle the disease. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period. The easy availability of vaccines at a comparatively lower cost is expected to propel market growth across the region. The Hepatitis A Vaccine market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by government policies and programs, especially in India and China. Moreover, the rise in the pediatric population and increased awareness about vaccination results in increasing demand for Hepatitis A Vaccine in emerging economies, such as India and China, which is expected to augment Asia Pacific's growth Hepatitis A Vaccine market.

Competitive Landscape:

The Hepatitis A Vaccine market is highly competitive, owing to the presence of major market players. The key Hepatitis A Vaccine player contributing to the global market's growth include GlaxoSmithKline, Merck & Co. Inc., Sanofi, Sinovac, Zhejiang Pukang, Changchun Institute of Biological, KM Biologics, IMBCA, ChangSheng, Convac, among others. The major players are adopting new expansion strategies for global growth in the Hepatitis A Vaccine market.

COVID-19 Impact: Negative impact on the global Hepatitis A Vaccine market

The outbreak of COVID-19 has negatively impacted the growth of the Hepatitis A Vaccine market globally. The disruption in the supply chain has majorly impacted the growth of the market amidst the pandemic. The escalated focus on COVID-19 vaccine development, product type, and distribution has led to de-escalation in Hepatitis A vaccines. Therefore, the COVID-19 pandemic has hampered the market value of the Hepatitis A Vaccine market in 2021

The global Hepatitis A Vaccine market report would provide an access to approximately 48 market data tables, 43 figures and 190 pages

Table of Contents

Scope and Methodology

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Supply Chain analysis
  • 5.3. PEST Analysis
  • 5.4. Pricing Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Product Type Segment
    • 7.1.2. Market attractiveness index, By Product Type Segment
  • 7.2. Inactivated Vaccine*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Live Attenuated Vaccine

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
    • 8.1.2. Market attractiveness index, By Application Segment
  • 8.2. Government Institution *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Private Sector
  • 8.4. Other

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. GlaxoSmithKline *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Merck & Co., Inc.
  • 11.3. Sanofi
  • 11.4. Sinovac
  • 11.5. Zhejiang Pukang
  • 11.6. Changchun Institute of Biological
  • 11.7. KM Biologics
  • 11.8. IMBCA
  • 11.9. ChangSheng
  • 11.10. Convac
  • List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us